Mannan, A Potential Therapeutic for Asthma

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$111,805.00
Award Year:
2009
Program:
STTR
Phase:
Phase I
Contract:
1R41HL090108-01A2
Award Id:
93912
Agency Tracking Number:
HL090108
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
CUMBERLAND PHARMACEUTICALS INC., 2525 WEST END AVE, STE 950, NASHVILLE, TN, 37203
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
069532880
Principal Investigator:
DUKHEE LEW
(901) 572-5370
DLEW@UTHSC.EDU
Business Contact:
LEO PAVLIV
() -
dkeeney@cumberlandpharma.com
Research Institution:
UNIVERSITY OF TENNESSEE HEALTH SCI CTR

UNIVERSITY OF TENNESSEE HEALTH SCI CTR
62 S. Dunlap, Suite 300
MEMPHIS, TN, 38163 6574

Nonprofit college or university
Abstract
DESCRIPTION (provided by applicant): The long-term goal of this application is to develop mannan derived from Baker's yeast as asthma therapy. The limitations of currently available immunomodulators are their toxicity at higher doses and the lack of benefi cial effect on airway smooth muscle (ASM) remodeling and therefore, new adjunctive therapeutics are needed. Initial findings in the P.I.'s laboratory have shown that mannan from S. cerevisiae, a carbohydrate-based prebiotic polymannose agent, inhibits airw ay inflammation, hyperreactivity (AHR) and ASM remodeling. Our central hypothesis is that mannan from S. cerevisiae is a novel class of immunomodulator that suppresses ASM remodeling. Studies are proposed 1) to determine the optimum dose and dose timing of mannan administered intranasally. 2) to determine the optimum dose and dose timining of mannan administered orally. The University of Tennessee College of Medicine Department of Pediatric Allergy/Immunology and Cumberland Emerging Technologies Inc (CET), an affiliate of Cumberland Pharmaceuticals Inc (CPI), are collaborating to identify and develop promising pharmaceutical therapies for treating and preventing asthma. The P.I. will conduct preclinical studies outlined in the proposal and CET will develop t he product for the preclinical and clinical trials. The knowledge gained from these studies will provide a novel class of adjuctive asthma therapy that will modulate ASM remodeling and will lead to a unique intranasal and oral products that will benefit as thmatics and patients with other related diseases. PUBLIC HEALTH RELEVANCE: Our central hypothesis is that mannan from S. cerevisiae is a novel class of immunomodulator that suppresses ASM remodeling. The long-term goal of this application is to develop ma nnan derived from Baker's yeast as asthma therapy.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government